Accra, Sept. 17, – The Food and
Drugs Authority (FDA) has alerted healthcare professionals and consumers, not
to distribute supply, or purchase any Hydrocortisone Injection B.P 100mg.
The product is labelled
Hydrocortisone Sodium Succinate Injection B.P 100mg, batch number 5AE01007,
manufactured by Ambica Pharma Sales, India with expiring date 09/2018.
A statement signed by Mrs Delese
A.A. Darko, the Chief Executive Officer of FDA and copied to the Ghana News
Agency on Monday, said the FDA laboratory analysis of the product found that
there was a lack of uniformity of content and related concerns, which makes it
unfit and un safe for purpose.
It said the Authority had
commenced the process of immediate withdrawal of the product from health
facilities and pharmaceutical suppliers that may have stocks, and hereby,
directed all such facilities to immediately check their medical suppliers,
quarantine any affected product, labelled as stated above and return them to
the suppliers or the FDA.
The statement assured the public
that the FDA would continue to do all within its mandate to ensure the safety
and efficacy of all products found in the Ghanaian market.
“Healthcare professionals and
suppliers of pharmaceutical products are encouraged to obtain any medications
they administer or provide to consumers/the general public, from reliable
sources that adhere to proper quality standards,” it said.
The FDA urges the public and
healthcare professionals to report all adverse reactions, quality problems or
any practice suspected to be against public health and safety to any of the
hotlines: 0299802932, 0299802933; short code – 4015 (on all networks except
GLO)
GNA

No comments:
Post a Comment